Home LiteratureArticle Details
PMID: 7545296 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM

Abstract

In the tumor-bearing host, T cells invariably fail to induce a clinically significant antitumor immune response. Although model systems support the existence of tumor peptide antigens, the molecular interactions critical for antigen presentation by the tumor cell remain unresolved. Here, we demonstrate that human follicular lymphoma cells are highly inefficient at presenting alloantigen despite their strong expression of major histocompatibility complex and low-to-intermediate expression of some adhesion and B7 costimulatory molecules. Activation of follicular lymphoma cells via CD40 induces or up-regulates both adhesion and B7 costimulatory molecules essential to repair this defect. More importantly, once primed, alloreactive T cells efficiently recognize unstimulated follicular lymphoma cells. Thus, correction of defective tumor immunity requires not only expression of major histocompatibility complex but also sufficient expression of multiple adhesion and costimulatory molecules.

MeSH Terms
Antigen-Antibody Reactions Antigen-Presenting Cells/immunology Antigens, CD/immunology Antigens, Differentiation, B-Lymphocyte/immunology CD40 Antigens Cell Adhesion/immunology Cells, Cultured Humans Isoantigens/biosynthesis Lymphocyte Activation Lymphoma, Follicular/immunology T-Lymphocytes/immunology Tumor Cells, Cultured Up-Regulation
Chemicals
Antigens, CD Antigens, Differentiation, B-Lymphocyte CD40 Antigens Isoantigens
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Schultze J L
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Cardoso A A
Freeman G J
Seamon M J
Daley J
Pinkus G S
Gribben J G
Nadler L M
References (28)
28 references, click to expand
  1. Role of B7-1 in mediating an immune response to myeloid leukemia cells.
    Blood. 1995 May 1;85(9):2507-15 PMID: 7537118
  2. CD40 ligand triggered interleukin-6 secretion in multiple myeloma.
    Blood. 1995 Apr 1;85(7):1903-12 PMID: 7535594
  3. Gene transfer as cancer therapy.
    Adv Immunol. 1995;58:417-54 PMID: 7741031
  4. The normal and malignant germinal centre.
    Clin Haematol. 1982 Oct;11(3):531-59 PMID: 6756733
  5. Expression of B cell activation antigens on normal and malignant B cells.
    Leukemia. 1987 Jan;1(1):9-15 PMID: 3118102
  6. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1).
    Cell. 1987 Dec 4;51(5):813-9 PMID: 3315233
  7. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells.
    J Immunol. 1990 Jun 15;144(12):4579-86 PMID: 1972160
  8. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.
    J Exp Med. 1991 Mar 1;173(3):721-30 PMID: 1847722
  9. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
    N Engl J Med. 1991 Nov 28;325(22):1525-33 PMID: 1944436
  10. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.
    Cell. 1992 Dec 24;71(7):1093-102 PMID: 1335364
  11. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.
    Science. 1993 Jan 15;259(5093):368-70 PMID: 7678351
  12. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.
    J Exp Med. 1993 Apr 1;177(4):925-35 PMID: 7681471
  13. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
    Nature. 1993 Apr 22;362(6422):755-8 PMID: 8469286
  14. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 PMID: 8097319
  15. Cancer vaccines.
    Immunol Today. 1993 Jun;14(6):310-6 PMID: 8397772
  16. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance.
    J Exp Med. 1993 Nov 1;178(5):1753-63 PMID: 7901318
  17. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
    Science. 1993 Nov 5;262(5135):909-11 PMID: 7694363
  18. New strategies for enhancing the immunogenicity of tumors.
    Curr Opin Immunol. 1993 Oct;5(5):719-25 PMID: 7694593
  19. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.
    Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11059-63 PMID: 7504293
  20. Costimulation of T cells for tumor immunity.
    Immunol Today. 1993 Oct;14(10):483-6 PMID: 7506034
  21. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells.
    J Immunol. 1994 Mar 15;152(6):2675-85 PMID: 7908301
  22. Tumour antigens. A new look for the 1990s.
    Nature. 1994 Jun 2;369(6479):357 PMID: 8018207
  23. Tumor antigens recognized by T lymphocytes.
    Annu Rev Immunol. 1994;12:337-65 PMID: 8011285
  24. The CD40 antigen and its ligand.
    Annu Rev Immunol. 1994;12:881-922 PMID: 7516669
  25. CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy.
    J Exp Med. 1994 Nov 1;180(5):1665-73 PMID: 7525835
  26. Tumor immunotherapy: the tumor cell as an antigen-presenting cell.
    Curr Opin Immunol. 1994 Oct;6(5):722-7 PMID: 7826527
  27. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.
    Curr Opin Immunol. 1994 Oct;6(5):741-5 PMID: 7826529
  28. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.
    J Exp Med. 1995 Feb 1;181(2):619-29 PMID: 7836917
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
1995-08-29
Pages
8200-4
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC41124
Subset
IM
Grants
NIAID NIH HHS · AI 35225 · United States
NCI NIH HHS · CA34183 · United States
NCI NIH HHS · CA40216 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]